Last reviewed · How we verify

Intralesional injection of bevacizumab

Khon Kaen University · Phase 3 active Small molecule

Intralesional injection of bevacizumab is a Monoclonal antibody (VEGF inhibitor) Small molecule drug developed by Khon Kaen University. It is currently in Phase 3 development for Intralesional treatment of solid tumors or lesions (investigational phase 3). Also known as: Avastin.

Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting new blood vessel formation to reduce tumor vascularity and nutrient supply.

Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting new blood vessel formation to reduce tumor vascularity and nutrient supply. Used for Intralesional treatment of solid tumors or lesions (investigational phase 3).

At a glance

Generic nameIntralesional injection of bevacizumab
Also known asAvastin
SponsorKhon Kaen University
Drug classMonoclonal antibody (VEGF inhibitor)
TargetVEGF (Vascular Endothelial Growth Factor)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

When injected directly into a lesion, bevacizumab binds to VEGF and prevents its interaction with VEGF receptors on endothelial cells. This inhibits angiogenesis—the formation of new blood vessels that tumors depend on for growth and metastasis. The intralesional route delivers high local concentrations directly to the target tissue while minimizing systemic exposure.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Intralesional injection of bevacizumab

What is Intralesional injection of bevacizumab?

Intralesional injection of bevacizumab is a Monoclonal antibody (VEGF inhibitor) drug developed by Khon Kaen University, indicated for Intralesional treatment of solid tumors or lesions (investigational phase 3).

How does Intralesional injection of bevacizumab work?

Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), inhibiting new blood vessel formation to reduce tumor vascularity and nutrient supply.

What is Intralesional injection of bevacizumab used for?

Intralesional injection of bevacizumab is indicated for Intralesional treatment of solid tumors or lesions (investigational phase 3).

Who makes Intralesional injection of bevacizumab?

Intralesional injection of bevacizumab is developed by Khon Kaen University (see full Khon Kaen University pipeline at /company/khon-kaen-university).

Is Intralesional injection of bevacizumab also known as anything else?

Intralesional injection of bevacizumab is also known as Avastin.

What drug class is Intralesional injection of bevacizumab in?

Intralesional injection of bevacizumab belongs to the Monoclonal antibody (VEGF inhibitor) class. See all Monoclonal antibody (VEGF inhibitor) drugs at /class/monoclonal-antibody-vegf-inhibitor.

What development phase is Intralesional injection of bevacizumab in?

Intralesional injection of bevacizumab is in Phase 3.

What are the side effects of Intralesional injection of bevacizumab?

Common side effects of Intralesional injection of bevacizumab include Local injection site reactions, Bleeding or hemorrhage, Wound healing complications, Systemic VEGF inhibition effects (if significant absorption).

What does Intralesional injection of bevacizumab target?

Intralesional injection of bevacizumab targets VEGF (Vascular Endothelial Growth Factor) and is a Monoclonal antibody (VEGF inhibitor).

Related